乌司他丁治疗慢性心力衰竭的疗效及其对患者血清炎症因子的影响

Clinical efficacy of ulinastatin in the treatment of chronic heart failure and impact on serum inflammatory factors

目的探讨乌司他丁治疗慢性心力衰竭(CHF)的临床疗效及其对患者血清炎症因子的影响。方法选择2014年1月至2015年4月期间在我院心内科住院治疗的88例CHF患者,采用数字表法随机将其分为观察组与对照组各44例,对照组予常规抗心衰治疗,观察组在此基础上联合应用乌司他丁治疗,比较两组患者治疗前后的左室射血分数(LVEF)水平、血清N末端B型钠尿肽前体(NT-pro BNP)水平,以及血清超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平,并比较临床疗效。结果治疗后两组患者的LVEF均明显提高,血清NT-pro BNP、hs-CRP、IL-6、TNF-α均明显降低,且上述指标在观察组明显优于对照组,差异均有统计学意义(P<0.05);观察组患者治疗总有效率为95.45%(42/44),明显高于对照组的86.36%(38/44),差异有统计学意义(P<0.05)。结论乌司他丁治疗慢性心力衰竭可抑制炎症反应,改善患者心功能状态,进而提高临床疗效。

Objective To investigate the clinical efficacy of ulinastatin in the treatment of chronic heart failure(CHF) and impact on serum inflammatory factors. Methods Eighty-eight patients with CHF treated in Department of Cardiology in our hospital from January 2014 to April 2015 were selected and randomly divided into two groups, with44 patients in each group. The control group was given conventional anti-heart failure treatment, while the observation group applied ulinastatin on the basis of the control group, The left ventricular ejection fraction(LVEF), serum N-terminal pro-B-type natriuretic peptide(NT-pro BNP), serum high-sensitivity C-reactive protein(hs-CRP), interleukin-6(IL-6) and tumor necrosis factor alpha(TNF-α) levels were compared between the two groups, as well as clinical efficacy. Results After treatment, the LVEF in both groups was significantly improved, while the serum NT-pro BNP,hs-CRP, IL-6, TNF-α levels were significantly reduced. The indexes in the observation group were significantly better than those in the control group(P<0.05). The effective rate of the observation group was significantly higher than that of the control group(95.45% vs 86.36%, P<0.05). Conclusion Ulinastatin in treatment of chronic heart failure can inhibit inflammation, improve heart function, and improve the clinical efficacy.